Cambridge, United States
Research view
Switch to patient viewChronic kidney disease: who works on it
Groups that published on this disease or run trials on it, from public registries and publications. Researchers appear by name only once their profile is published.
Find fellow researchers
One card per institution. Pick a target to see only the groups that work on it.
- All targets
- SGLT2 24
- GLP-1 8
- NLRP3 0
- NRF2 1
- PI3K 0
- APOL1 3
- AKT 0
- STAT3 1
- mTOR 1
- PPAR 0
- AMPK 0
- SIRT1 0
- HIF-1 0
- TLR4 0
- STING 0
- MAPK 0
- CTNNB1 0
- TP53 0
- ERK 0
- GPX4 0
- IL-6 3
- VEGF 0
- IL-1 1
- JAK 0
- JNK 0
- TNF 1
- DPP-4 0
- EGFR 0
- YAP 0
- FGFR 0
- PCSK9 0
- APOE 0
- PINK1 0
- TFEB 0
- BCMA 3
- HMGB1 0
- HSP90 0
- BDNF 0
- GIP 0
- CD40 0
- CD47 0
- COX-2 0
- IL-17 1
- PKM2 0
- PSMA 0
- ABL1 0
- CCR5 0
- EZH2 0
- METTL3 0
- MMP-9 0
- PKD1 0
- PTEN 0
- SNCA 0
- ANGPTL3 0
- BCL-2 0
- CD19 1
- CD38 0
- CDK4/6 0
- CXCR4 0
- FTO 0
Paris, France
Baltimore, United States
Boston, United States
Guangzhou, China
Mayo Clinic · Rochester, United States
Team details appear once the team leader joins.
Is this your team? Claim it
Latest publication · Br J Haematol, May 2026Predictors of renal response in AL amyloidosis following anti-plasma cell therapy: The impact of baseline serum free light chain levels and light chain isotype.
Stockholm, Sweden
The University of Sydney · Sydney, Australia
Team details appear once the team leader joins.
Is this your team? Claim it
Latest publication · BMC Infect Dis, Dec 2025Effectiveness comparison of nirmatrelvir/ritonavir versus molnupiravir in COVID-19 patients with comorbidities in Taiwan: a multi-centre electronic health record study.
Toronto, Canada
Seattle, United States
Ann Arbor, United States
London, United Kingdom
Shanghai, China
Copenhagen, Denmark
Berlin, Germany
Beijing, China
Dallas, United States
Shanghai, China
Sydney, Australia
Groningen, Netherlands
Houston, United States
Cleveland, United States
Singapore, Singapore
Stanford, United States
24 of 4,752 institutions, ordered by recent publications and open trials. This is not a ranking of quality.
Running research funding
Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.
European Commission (Horizon Europe) · HORIZON-ERC
Deciphering the gene regulation of oxygen homeostasis and human fitness (ErythrO2Reg)
The disease is named only in the funder's project summary, not in the title.
European Commission (Horizon Europe) · HORIZON-TMA-MSCA-DN
Next-generation therapeutics for vascular diseases (TIE2gether)
The disease is named only in the funder's project summary, not in the title.
European Commission (Horizon Europe) · HORIZON-ERC
Formaldehyde crosslink exposure and genomic ageing (FORCE)
The disease is named only in the funder's project summary, not in the title.
European Commission (Horizon Europe) · HORIZON-ERC
Early Inflammation in Fibrotic Niches of Chonic Kidney Disease (InFibrosis)
European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF
5 of 52 running projects, newest first. Listed amounts together: €145.3m.
Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.
Who stopped a trial, and why
Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.
Suspended
Molecular and Clinical Profile of Diabetes Mellitus and Its Complications
“Recruitment temporarily paused.”Registry text, quoted unchanged. Source
Suspended
“Sponsor decision”Registry text, quoted unchanged. Source
Terminated
“Unanticipated operational challenges. No safety concerns.”Registry text, quoted unchanged. Source
Terminated
“Interim futility analysis showed primary endpoint not achieved”Registry text, quoted unchanged. Source
Terminated
ARTEMIS: Ravulizumab to Protect Patients With CKD From CSA-AKI and MAKE
“The ALXN1210-CSA-AKI-318 trial was discontinued on 29-Apr-2026 due to lack of efficacy in this overall study universe / patient population.”Registry text, quoted unchanged. Source
Terminated
“Inadequate treatment response observed in preliminary data did not justify enrolling further study participants”Registry text, quoted unchanged. Source
Withdrawn
“The study was withdrawn because the protocol was revised and would be replaced by an updated study design, prior to participant enrollment.”Registry text, quoted unchanged. Source
Terminated
Solv Multi-Pass Hemodialysis System In-Center Clinical Study
“Due to funding the study has been stopped. All subjects enrolled have completed the follow-up and have exited the study.”Registry text, quoted unchanged. Source
Withdrawn
Comparing Natriuretic Effects of ER Torsemide to IR Torsemide in Patients With Heart Failure
“No participants enrolled”Registry text, quoted unchanged. Source
Withdrawn
“No recruitment”Registry text, quoted unchanged. Source
Trials that share participant data
Trials whose registry record says individual participant data (IPD) will be shared.
Search by method
Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.
- Single-Cell Analysis 29
- Organoids 10
- Mendelian Randomization Analysis 78
- CRISPR-Cas Systems 5
- Gene Expression Profiling 88
- Sequence Analysis, RNA 4
- Whole Genome Sequencing 2
- Exome Sequencing 19
- Proteomics 103
- Metabolomics 91
- Mass Spectrometry 18
- Flow Cytometry 10
- Immunohistochemistry 19
- Liquid Biopsy 2
- Positron-Emission Tomography 5
- Magnetic Resonance Imaging 70
- Machine Learning 176
- Deep Learning 22
- Cohort Studies 553
- Genome-Wide Association Study 79
Paste an abstract
See which targets of this disease your abstract mentions, and go to the people working on them.
Matched in your browser only. The text is not sent, saved or logged.
Sources: ClinicalTrials.gov, EU CTR, OpenAlex, PubMed, NIH RePORTER, CORDIS. Machine-matched links are labelled.